TELATELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's a…
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 TELA Bio (TELA) Q2 2026 Earnings Call Transcript Revenue declined 4% as OviTex PRS unit volumes fell, but international sales surged 26%. | ||
TELA Bio Inc (TELA) (Q2 2026) Earnings Call Highlights: Navigating PRS Headwinds and Strategic ... Despite a 4% revenue dip, TELA Bio Inc (TELA) sees strong international growth and improved gross margins while executing a cost-reduction plan to extend its cash runway. | ||
 TELA Bio, Inc. Q2 2026 Earnings Call Summary Moby summary of TELA Bio, Inc.'s Q2 2026 earnings call | ||
 TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates TELA Bio (TELA) delivered earnings and revenue surprises of -17.65% and -3.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates Puma Biotech (PBYI) delivered earnings and revenue surprises of +90.00% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Earnings Release: Here's Why Analysts Cut Their TELA Bio, Inc. (NASDAQ:TELA) Price Target To US$2.25 TELA Bio, Inc. ( NASDAQ:TELA ) shareholders are probably feeling a little disappointed, since its shares fell 10.0% to... | ||
TELA Bio, Inc. Q1 2026 Earnings Call Summary Moby summary of TELA Bio, Inc.'s Q1 2026 earnings call | ||
TELA Bio Inc (TELA) Q1 2026 Earnings Call Highlights: Strong European Growth and Strategic U.S. ... Despite challenges in the U.S. market, TELA Bio Inc (TELA) reports significant revenue growth and strategic advancements in its product portfolio. | ||
 TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates TELA Bio (TELA) delivered earnings and revenue surprises of -50.00% and +3.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +36.36% and +68.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock? | ||